• 1
    U.S. Preventive Services Task Force Chemoprevention of breast cancer: recommendations and rationale. Ann Intern Med. 2002; 137: 5658.
  • 2
    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90: 13711388.
  • 3
    Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer. 2002; 3: 153159.
  • 4
    Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999; 91: 18291846.
  • 5
    Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003; 95: 526532.
  • 6
    Gordon T, Moore FE, Shurleff D, Dawber TR. Some methodological problems in the long-term study of cardiovascular disease: observation on the Farminham Study. J Chron Dis. 1959; 10: 186206.
  • 7
    Heilbrun LK, Nomura A, Stemmermann GN. The effects of nonresponse in a prospective study of cancer. Am J Epidemiol. 1982; 116: 353363.
  • 8
    Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351: 543551.
  • 9
    Helzlsouer KJ, Alberg AJ, Huang HY, et al. Serum concentrations of organochlorine compounds and the subsequent development of breast cancer. Cancer Epidemiol Biomarkers Prev. 1999; 8: 525532.
  • 10
    Anderson S, Ahnn S, Duff K, NSABP Breast Cancer Prevention Trial risk assessment program. NSABP Biostatistical Center Technical Report, 1992. Pittsburgh: Department of Biostatistics, University of Pittsburgh, 1992.
  • 11
    McAlister FA, Straus SE, Guyatt GH, Haynes RB. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. JAMA. 2000; 283: 28292836.
  • 12
    Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995; 310: 452454.
  • 13
    Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001; 93: 358366.
  • 14
    Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer. 2004; 100: 18001806.
  • 15
    Smith TJ, Hillner BE. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women. J Clin Oncol. 2000; 18: 284286.
  • 16
    Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. N Engl J Med. 2003; 348: 16721680.